The US is the largest pharmaceutical markets in the world. Driven by factors, such as large healthcare spending, high per-capita income, and strong investments, the pharmaceutical market in the US has been witnessing an upward surge. Despite recession, the market continued to perform in an effective manner. Generics too have enlarged their share in the overall pharmaceutical market, in terms of both revenue and prescriptions. The US generic drugs market has been growing at a fast pace on the back of factors, such as demand for cost-effective medications, patent expiration of blockbuster drugs, and the government support.
The US generics market is anticipated to grow at a CAGR of around 10% during 2010-2013, says our recent research report “Booming US Generic Drug Market”. Currently, the market is witnessing significant developments in the form of new product categories that are attracting huge investments from both public and private players. The US government has welcomed their arrivals and extended support in the form of approvals and incentives. In terms of future scenario, major pharmaceutical players are likely to spend heavily on research and development as present market is in dynamic in nature and requires innovative products. Besides, these players will be consistently reviewing patent regime as through proactive approach, they will be able to launch their drugs first.
The generics market in the US has good growth potential in various therapy segments, which have attracted investments and market revenue in recent times. In this regard, our report provides rational analysis of various factors, which will drive the generics market in the US during the forecast period.
Overall, the report covers all the important aspects of the US generics market and provides an in-depth analysis on emerging trends, such as injectable generics, anti-counterfeit coalition, and bio-generics among others. It also provides valuable information to pharmaceutical & generics companies and investors looking to enter this market. Facts and figures regarding market size, growth, share, regulatory environment, and trends in technology development have been thoroughly analyzed in the report to provide clients a comprehensive overview of the market.
The US generics market is anticipated to grow at a CAGR of around 10% during 2010-2013, says our recent research report “Booming US Generic Drug Market”. Currently, the market is witnessing significant developments in the form of new product categories that are attracting huge investments from both public and private players. The US government has welcomed their arrivals and extended support in the form of approvals and incentives. In terms of future scenario, major pharmaceutical players are likely to spend heavily on research and development as present market is in dynamic in nature and requires innovative products. Besides, these players will be consistently reviewing patent regime as through proactive approach, they will be able to launch their drugs first.
The generics market in the US has good growth potential in various therapy segments, which have attracted investments and market revenue in recent times. In this regard, our report provides rational analysis of various factors, which will drive the generics market in the US during the forecast period.
Overall, the report covers all the important aspects of the US generics market and provides an in-depth analysis on emerging trends, such as injectable generics, anti-counterfeit coalition, and bio-generics among others. It also provides valuable information to pharmaceutical & generics companies and investors looking to enter this market. Facts and figures regarding market size, growth, share, regulatory environment, and trends in technology development have been thoroughly analyzed in the report to provide clients a comprehensive overview of the market.
- 1. Analyst View
- 2. Research Methodology
- 3. Market Overview
- 4. Industry Performance and Forecast to 2013
- 4.1 Branded vs Generics
- 4.2 Generics Drugs Market
- 4.2.1 By Value
- 4.2.2 By Volume
- 5. Market Potential of Generics Drugs in Key Therapies Segments
- 5.1 Lipid Regulators
- 5.2 Antipsychotics
- 5.3 Angiotensin II Receptor
- 5.4 Anti Depressants
- 5.5 Human Insulin
- 5.6 Proton Pump Inhibitors
- 5.7 Erythropoietin
- 6. Regulatory Environment
- 6.1 Drug Efficacy Study Implementation (DESI) Program
- 6.2 Hatch-Waxman Act
- 6.3 Patent Infringement Litigations
- 6.4 Para IV & the 180-day Marketing Exclusivity
- 6.5 FDA Requirements
- 6.6 Generic Initiative for Value & Efficiency (GIVE)
- 6.7 Healthcare Bill 2010
- 6.8 Ban on “Pay for delay” Settlements
- 6.9 Patient Protection and Affordable Care Act
- 7. Emerging Market Trends
- 7.1 Biogenerics/Biosimilar
- 7.2 Anti-counterfeit Coalition
- 7.3 Injectable Generics
- 7.4 Patent Expiration
- 7.5 Asthma & COPD Drugs
- 8. Key Players
- 8.1 Teva Pharmaceuticals USA
- 8.2 Watson Pharmaceuticals, Inc.
- 8.3 Mylan Laboratories Inc.
- 8.4 Pfizer Inc.
- 8.5 Sandoz Inc. (Novartis)
- List of Figures:
- Figure 4-1: Share of Branded and Generics Drugs in Prescription Market (2008 & 2009)
- Figure 4-2: Generics Drugs Market (Billion US$), 2009-2013
- Figure 4-3: Share of Generics and Branded Drugs in Pharma Market (By Sales Value), 2009
- Figure 4-4: Share of Generics and Branded Drugs in Prescription Market (By Sales Volume), 2009
- Figure 6-1: Generic Drugs Approval Process
- Figure 7-1: Biogenerics Market (Billion US$), 2008 & 2013
- Figure 7-2: Forecast for Share of Biogenerics Market by Drugs Type (2016)
- Figure 8-1: Share of Key Players in Generics Market
- List of Tables:
- Table 5-1: Top Therapeutic Categories by Sales (Billion US$), 2009
- Table 5-2: Patent Expiration of Key Lipid Regulators
- Table 5-3: Patent Expiration of Key Antipsychotic Drugs
- Table 5-4: Patent Expiration of Key Angiotensin II Receptor
- Table 5-5: Patent Expiration of Key Antidepressants Drugs
- Table 5-6: Patent Expiration of Key Human Insulin Drugs
- Table 5-7: Patent Expiration of Key Proton Pump Inhibitors
- Table 7-1: Patent Expiration for Biopharmaceuticals
- Table 7-2: Blockbuster Drugs Going Off-patent Globally (2010 to 2012)
Other selected research from the 'USA' category:
The eHealth Market in the US: Understanding Physician and Consumer Needs
The eHealth Market in the US analyzes physician and consumer Internet use. It examines the Internet penetration, online information requirements and mobile technology use of both groups. It also looks at trends and physician/consumer attitudes. There appears to be significant potential for further uptake of online services, most notably in the areas of ePrescribing, eDetailing and online CME. Learn More
Website Benchmarking Tool: US and European Targeted Websites
Many prescribers rely on websites provided by pharmaceutical companies when searching for treatment information. Consumers also rely heavily on online resources when searching for disease and treatment information. Websites that tailor their site content to address the specific needs of their target audience will experience greater retention of site visitors. Learn More
Other selected research from the 'Markets' category:
The Top 10 Generics Companies: Strategic insight, growth opportunities and competitive dynamics in the US and Europe
This report provides insights into the top 10 generic companies strengths, weaknesses, opportunities and threats in the generic pharmaceutical market, allowing you to tailor the best practice strategies of the generic industry`s leading players to your company`s needs. Learn More
Generic Competition 2007 to 2011- The impact of patent expiries on sales of major drugs
This unique report will describe in detail which major selling drugs will be affected by patent expiry and the likely financial effect on the producer company. Learn More